<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873493</url>
  </required_header>
  <id_info>
    <org_study_id>M18-803</org_study_id>
    <secondary_id>2018-002179-17</secondary_id>
    <nct_id>NCT03873493</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia</brief_title>
  <official_title>A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and efficacy of venetoclax plus ibrutinib for participants
      with T-cell Prolymphocytic Leukemia (T-PLL) and follows a 2-stage design as follows:

      Stage 1: Enroll up to 14 participants and move to Stage 2 if 4 or more subjects meet
      protocol-specified response criteria. Response assessment will be performed on a continued
      basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24
      disease assessment.

      Stage 2: Enroll up to an additional 23 participants with previously untreated or relapsed or
      refractory T-PLL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">December 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants achieving complete remission (CR), CR with incomplete bone marrow recovery (CRi), or partial response (PR) as their best response (per investigator assessment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>PFS is defined as the time from the participant's first dose of study drug to the date of documented disease progression, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>TPP is defined as the time from the date of the participant's first dose of study drug to the date of documented disease progression; does not include deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>DOR defined as the time from the date of first response (CR, CRi, or PR) to the date of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>OS is defined as the time from the date of the participant's first dose of study drug to to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reaching Autologous or Allogeneic Transplantation</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Number of participants reaching autologous or allogeneic transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>EFS is defined as time from participant's first dose of study drug to disease progression, death, or discontinuation of treatment for any reason.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Leukemia</condition>
  <condition>T-cell Prolymphocytic Leukemia (T-PLL)</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Venetoclax + Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 400 mg, potentially up to 600 mg, orally once daily (QD) plus Ibrutinib 420 mg dosed orally QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet; oral</description>
    <arm_group_label>Venetoclax + Ibrutinib</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>capsule; oral</description>
    <arm_group_label>Venetoclax + Ibrutinib</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adequate liver, kidney and hematology function per laboratory values as described in
             the protocol.

          -  Diagnosis of T-cell prolymphocytic leukemia (T-PLL) that requires treatment.

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.

          -  Negative for human T-cell lymphotropic virus, type 1.

          -  Received prior alemtuzumab (unless unsuitable or unavailable).

          -  Has no malignancies other than T-PLL that:

               -  currently require systemic therapies;

               -  were not previously treated with curative intention (unless the malignant disease
                  is in a stable remission due to the discretion of the treating physician); or

               -  developed signs of progression after curative treatment.

        Exclusion Criteria:

          -  History of or current decompensated cirrhosis including Child-Pugh class B or C,
             ascites, hepatic encephalopathy, or variceal bleeding.

          -  Has human T-cell lymphotropic virus, type 1.

          -  Prior allogeneic stem cell transplant within 6 months of study drug administration and
             requirement for graft versus host therapy.

          -  Has an uncontrolled or active infection.

          -  Previously treated with a B-cell lymphoma (BCL)-2 inhibitor.

          -  Received a prohibited therapy within the specified time frame as described in the
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 207728</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester /ID# 207692</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center /ID# 207746</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Ctr /ID# 209554</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien /ID# 208497</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital /ID# 208108</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud /ID# 208731</name>
      <address>
        <city>Pierre Benite CEDEX</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez /ID# 208726</name>
      <address>
        <city>Lille CEDEX</city>
        <state>Hauts-de-France</state>
        <zip>59045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere /ID# 208730</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne /ID# 208834</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto I /ID# 212254</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Giuliano Isontina /ID# 211487</name>
      <address>
        <city>Trieste</city>
        <zip>34129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum /ID# 207989</name>
      <address>
        <city>Eindhoven</city>
        <zip>5600 PD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen /ID# 207990</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. James University Hospital /ID# 211265</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital /ID# 211263</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford Univ Hosp NHS Trust /ID# 211264</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-cell Prolymphocytic Leukemia (T-PLL)</keyword>
  <keyword>Cancer</keyword>
  <keyword>venetoclax</keyword>
  <keyword>ibrutinib</keyword>
  <keyword>Relapsed or Refractory T-lymphoid malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

